Volume 2, Number 2 (June 2016)                   mazu-cmm 2016, 2(2): 34-39 | Back to browse issues page



DOI: 10.18869/acadpub.cmm.2.2.8
PMID: 28681018
PMCID: PMC5490303

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shokohi T, Badali H, Amirrajab N, Ataollahi M R, Kouhpayeh S A, Afsarian M H. In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran. mazu-cmm. 2016; 2 (2) :34-39
URL: http://cmm.mazums.ac.ir/article-1-105-en.html

Abstract:   (1606 Views)

Background and Purpose: Candida albicans is the most common causative agent of candidiasis. Candidiasis
management is dependent on the immune status of the host, severity of disease, and the choice of antifungal drug.
Antifungals, specifically triazoles, are widely administered for the treatment of invasive fungal infections. Herein, we
aimed to evaluate the in vitro susceptibility of C. albicans isolates to fluconazole (FLZ), itraconazole (ITZ), voriconazole
(VRZ), amphotericin B (AMB), and Caspofungin (CAS).
Materials and Methods: A total of 44 clinical strains of C. albicans were collected from 36 patients admitted to four
hospitals in Mazandaran Province, Iran. The in vitro antifungal susceptibility testing was performed based on the Clinical
and Laboratory Standards Institute methods.
Results: Generally, 34 isolates were susceptible to all the five antifungal drugs, while four isolates were susceptible or
susceptible dose-dependent (SDD) and six isolates were SDD or resistant to these antifungals. The lowest minimum
inhibitory concentration (MIC; 0.016 μg/ml) belonged to AMB and the highest MIC was for FLZ (16 μg/ml). The lowest
MIC50 (0.063 μg/ml) was related to ITZ and the lowest MIC90 (0.25 μg/ml) pertained to CAS; in addition, the highest
MIC50 (1 μg/ml) and MIC90 (4 μg/ml) were for FLZ. Four of the isolates showed resistance to both FLZ and VRZ,
separately, and five isolates were resistant to ITZ. Caspofungin showed potent activity against more than 95% of the C.
albicans isolates.
Conclusion: Overall, we reported 9.1% resistance to FLZ and VRZ, 11.3% resistance to ITZ and AMB, and 4.6%
resistance to caspofungin. Our finding is in agreement with previous observations proposing that C. albicans isolates
develop resistance to some antifungal drugs such as FLZ since they are widely used as prophylaxis.

Full-Text [PDF 397 kb]   (426 Downloads)    
Type of Study: Original Articles | Subject: Anti Microbial Research
Received: 2016/09/3 | Accepted: 2016/10/9 | Published: 2016/10/9

Add your comments about this article : Your username or email:
Write the security code in the box

Send email to the article author


© 2015 All Rights Reserved | Current Medical Mycology